sur NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides Highlights NV-387's Potential Against COVID-19
SHELTON, CT / ACCESSWIRE / July 24, 2024 / NanoViricides, Inc. (NYSE American:NNVC), a clinical stage leader in antiviral nanomedicines, highlights the strong safety and effectiveness of its lead drug candidate NV-387 against coronaviruses.
President Joe Biden’s recovery from a new COVID variant underscores the need for potent drugs, a gap NV-387 aims to address. COVID remains a significant health challenge in the U.S., with biannual waves of new variants causing higher fatalities and hospitalizations than Influenza.
In animal studies, NV-387 significantly improved survival rates compared to Remdesivir (Veklury®, Gilead). IV administration of NV-387 in infected rats showed a 180% survival increase, versus Remdesivir's 50%. Oral NV-387 also demonstrated high effectiveness with an 88% increase.
Despite the focus on vaccines and antibodies, limitations have emerged. Currently, Paxlovid™ (Pfizer) is the only available oral COVID drug, though its clinical effectiveness is questionable. NV-387's broad antiviral spectrum and safety indicate it may fill a crucial public health need.
NanoViricides is pursuing collaborations to advance NV-387 towards regulatory approval for multiple antiviral uses. Phase I trials in India showed excellent safety and tolerability for NV-387 in oral formulations, without adverse events at high dosages.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NanoViricides, Inc.